Drug profile · INN
satavaptan
AQUILDA
satavaptan (AQUILDA) is a vasopressin v2 receptor antagonist.
EMA: application withdrawn
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — satavaptan
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
satavaptan (AQUILDA) is a vasopressin v2 receptor antagonist.
Key facts
INN satavaptan
Brand AQUILDA
Mechanism Vasopressin V2 receptor antagonist
Target Vasopressin V2 receptor
Mechanism of action
Vasopressin V2 receptor antagonist
Primary target: Vasopressin V2 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is satavaptan?
satavaptan (AQUILDA) is a vasopressin v2 receptor antagonist.
What is the brand name for satavaptan?
AQUILDA is a marketed brand name for satavaptan. Check FDA Drugs@FDA for the current US label holder and prescribing information.